50% off Premium Yearly
Too speculative. They lose money.
Stock price when the opinion was issued
As of Jun 12, 2026. Market Open.
Up 152% last year. They got FDA approval for one of their top drugs last year to treat a lung condition. It pulled back 18% last month due to a disappointing trial result in a drug. Worth watching this.
Build your watch list
Sign in to track investmentsyou care about
CNBC
RN Croft Financial Group
5i Research
Stockchase Premium
Private Wealth Management, ScotiaMcleod
Too speculative. They lose money.